About:

Medicamentics is specialized in innovative clinical trial design, analysis, and execution for the pharmaceutical and medical device industry.

Our team has extensive experience in working with clinical investigators, scientific domain experts, and regulatory consultants in the design, simulation, and implementation of adaptive clinical trials.

We act as a key partner in biostatistics, statistical consultingand data science for developers of medicines and medical devices.

Team:

Mukesh Kumar, PhD
Founder, CEO

An innovator cum entrepreneur with over 13 years of extensive work experience and has managed a range of MedTech/biotech products. Having developed various innovative projects to address unmet clinical needs, has the breadth of experience to transfer the research output from concept/laboratory to prototyping to production stage - clinical/industrial applications. Extensive background in innovative and challenging translational projects with experience of product/business development, quality control, grant writing, advanced manufacturing processes, project management, licensing and healthcare strategy.

Helped develop medical device/diagnostic products based on electroanalytical measurements (www.bailriggd.com), immunochemical measurements, molecular diagnostic/testing, personalised oncology treatment.

Mukesh holds BEng 1st class & PhD - both from Lancaster University UK, MIT Technology Review’35 Europe 2017 Finalist, Rice Business Plan Competition (RBPC) 2012 Finalist, won various competitive innovation grants in UK/Europe and co-authored a number of high impact journals and patents.

Professor Andrew Titman, PhD:

Andrew’s primary research interests are in survival and event history analysis with a particular focus on the analysis of multi-state survival data. His work in this area has included development of methods to account for misclassified disease diagnoses, time non-homogeneity and non-Markov behaviour of the underlying process. Current work includes methods for accounting for informative observation times and applications to the design and analysis of oncology trials and to health economic decision modelling. He also has a continuing interest in latent variable modelling, with application to the validation of health-related quality of life questionnaires, health screening instruments and the analysis of ordinal longitudinal patient reported outcome data.

Eric J Culbert, PhD

Eric Culbert, PhD, is a graduate of the University of Glasgow, and of University College, London, where he specialised in immunology, and mechanisms of autoimmunity. He has spent more than 30 years in the Pharma and Biotech industries with ICI Pharmaceuticals, AstraZeneca, and MedImmune, as well as holding CEO and CSO roles with various biotech start-ups focussing on inflammatory diseases and oncology. More recently, Dr Culbert has been involved in reviewing, coaching and mentoring younger entrepreneurs in establishing start up ventures at Stevenage Bioscience catalyst, Alderley Park and the University of Manchester.

Dr Culbert has a broad experience across research and the early phases of clinical development in a range of diseases. He led a research team which produced a novel immunomodulator for the treatment of rheumatoid arthritis, and was a member of the development team which took the agent up to a successful multinational Phase 2a study. He played a leading role in generating the strategy which led to the acquisition of Cambridge Antibody Technology by AstraZeneca in 2006. Dr Culbert’s research interests have included T cell signalling pathways, antigen presentation, costimulatory molecules, monoclonal antibodies, and cell interactions in oncology.

Nikos Tsikouras – Research Student

His current research interests revolve around optimal decision-making applied to the field of clinical trial research.

Nikos graduated with first degree in 2020 after doing a 4-year-course on Mathematics, which specialised in Statistics.

He graduated with a distinction from the MSc in Statistics at Imperial College London in 2021. This MSc provided him with outstanding training in both theoretical and applied statistics. In 2022 he graduated with a distinction from MRes with STOR-i at Lancaster University.